AI주식인사이트AI Stock Insight
C

셀레믹스

331920KOSDAQ

46.0 / 100

Reference Date: 2026-10-23

Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellomics is a company specializing in DNA sequencing and molecular cloning technologies based on molecular biology, utilizing its innovative MSSIC (Massively Separated and Sequence Identified Cloning) technology to enable low-cost, high-throughput analysis. The company offers key products such as Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions, which are widely used in healthcare, pharmaceuticals, agriculture, and other fields.

Number of Employees

41people

Average Salary

60.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
4.87Industry Average 1.200.0Point

4.1x industry avg (risky)

ROE
-16.08Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
0.48Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼6.0% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.8% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 6.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (47%)

Current 10,020Won52-week high 18,20052-week low 2,580
1-month return1.0Point

1m -13.10% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral주식매수선택권부여에관한신고2026-10-06